Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4507146 | 0.84 | L3MBTL1 (0.50) | L3MBTL1KMT2AALDH1A1 | |
| SCHEMBL11458699 | 0.83 | CYP1A2 (0.42) | L3MBTL1TDP1LMNA | |
| SCHEMBL6555619 | 0.82 | LMNA (0.40) | L3MBTL1TDP1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL13014972 | 0.82 | MEN1 (0.46) | L3MBTL1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL908518 | 0.82 | HDAC3 (0.44) | KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL1526022 | 0.82 | KMT2A (0.64) | KMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL1968557 | 0.81 | TDP1 (0.42) | L3MBTL1TDP1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL268626 | 0.81 | TDP1 (0.42) | L3MBTL1TDP1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL11773513 | 0.79 | CXCR1 (0.44) | L3MBTL1TDP1SMN1; SMN2KMT2AMEN1 | |
| Propane SCHEMBL27580660 | 0.79 | L3MBTL1 (0.50) | L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101678019-A | piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA NV | 2010-03-24 | — | — | CN | disclosed |
| EP-1915148-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPATHIES AND RELATED DISORDERS | DOV Pharmaceutical, Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| US-20070149599-A1 | Polymorphs of bicifadine hydrochloride | DOV PHARMACEUTICAL, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070082938-A1 | Polymorphs of bicifadine hydrochloride | DOV PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | LIPPA ARNOLD S | 2007-04-12 | — | — | US | disclosed |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | LIPPA ARNOLD S | 2007-04-12 | — | — | US | disclosed |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | LIPPA ARNOLD S | 2007-04-12 | — | — | US | disclosed |
| WO-2007014264-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPATHIES AND RELATED DISORDERS | DOV PHARMACEUTICAL, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007014264-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPATHIES AND RELATED DISORDERS | DOV PHARMACEUTICAL, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-7094799-B2 | A single, thermodynamical stable crystal structure, is crystallized from a cooled and agitated solvent solution, analgesic drug for reducing pain | DOV PHARMACEUTICAL, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| EP-1562900-A4 | POLYMORPHS OF BICIFADINE HYDROCHLORIDE | DOV PHARMACEUTICAL INC (US) | 2006-07-12 | — | — | EP | disclosed |
| CN-1735594-A | Polymorphs of bicifadine hydrochloride | DOV PHARMACEUTICALS INC (US) | 2006-02-15 | — | — | CN | disclosed |
| EP-1562900-A1 | POLYMORPHS OF BICIFADINE HYDROCHLORIDE | DOV Pharmaceutical Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004043920-A1 | POLYMORPHS OF BICIFADINE HYDROCHLORIDE | DOV PHARMACEUTICALS, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040102638-A1 | Polymorphs of bicifadine hydrochloride | EUTHYMICS BIOSCIENCE, INC. | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149599-A1 | Polymorphs of bicifadine hydrochloride | SF3B5, SFPQ, BBC3 | L3MBTL1 3038/4885TDP1 3773/4885SMN1; SMN2 4019/4885 |
| US-20070082938-A1 | Polymorphs of bicifadine hydrochloride | SF3B5, SFPQ, BBC3 | L3MBTL1 3038/4885TDP1 3773/4885SMN1; SMN2 4019/4885 |
| US-20040102638-A1 | Polymorphs of bicifadine hydrochloride | SF3B5, SFPQ, BBC3 | L3MBTL1 3038/4885TDP1 3773/4885SMN1; SMN2 4019/4885 |
| US-20070082939-A1 | Methods and compositions for the treatment of neuropathies and related disorders | ACHE, LTC4S, CCR5 | L3MBTL1 2187/4885TDP1 1322/4885SMN1; SMN2 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.